Montai Therapeutics develops small molecule medicines for chronic diseases by leveraging AI-enabled drug discovery against diverse, untapped chemistry. Their CONECTA platform analyzes over a billion Anthromolecule compounds to predictably identify highly efficacious and selective oral drug candidates. This approach targets complex biological pathways previously considered undruggable with traditional small molecules.
Funding
$60M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Developing effective oral medications for chronic diseases is challenging due to the complex biological pathways involved and the limitations of traditional medicinal chemistry in identifying suitable small molecule drugs. Many validated biological pathways are considered "undruggable" with conventional approaches, leaving a significant portion of patients with unmet needs.
Solution
Montai Therapeutics is developing small molecule drugs for chronic diseases by leveraging its CONECTA platform, which combines machine learning and a library of Anthromolecule™ compounds. Anthromolecules, bioactive molecules humans have chronically consumed, offer a diverse chemical space for engaging complex biological targets. Montai's AI tools and end-to-end automation enable the predictable discovery and optimization of drug leads within this space, identifying molecules that can modulate validated pathways with precision. This approach aims to create effective oral medicines for conditions that have historically been difficult to treat.
Target Audience
Montai's primary target audience includes patients suffering from chronic diseases, particularly those with inflammation and autoimmune disorders, as well as pharmaceutical companies seeking partnerships to develop novel therapies.
Features
- CONECTA™ platform: An AI-powered drug discovery system that matches chemistry to biology for superior outcomes.
- AnthroGraph: Multidimensional characterization and scoring of Anthromolecules across properties essential to drug development.
- Bioactivity Atlas: Chemical machine learning-powered mapping of bioactive connections between Anthromolecules and disease pathways.
- Pathway Solutions: Identification of molecules that modulate pathways underlying chronic disease.
- AI-driven lead optimization: Prioritization of drug leads based on drug-like properties and potential for efficacy.
- Large library of Anthromolecules: Access to a diverse chemical space derived from molecules humans have chronically consumed.